Occupancy of agonist drugs at the 5-HT1A receptor (Q44777682)

6 December 2017

title

Occupancy of agonist drugs at the 5-HT1A receptor (English)

1 reference

6 December 2017

2

Eugenii A Rabiner

1 reference

6 December 2017

R Alexander Bantick

1

1 reference

6 December 2017

Ella Hirani

3

1 reference

6 December 2017

Michiel H de Vries

4

1 reference

6 December 2017

Susan P Hume

5

1 reference

6 December 2017

Paul M Grasby

6

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

6 December 2017

published in

Neuropsychopharmacology

1 reference

6 December 2017

volume

29

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

847-859

1 reference

Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

[3H]WAYâ 100635 for 5â HT1A receptor autoradiography in human brain: a comparison with [3H]8â OHâ DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

5-HT1A receptor agonists: recent developments and controversial issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Parametric imaging of ligand-receptor binding in PET using a simplified reference region model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Different tonic regulation of neuronal activity in the rat dorsal raphe and medial prefrontal cortex via 5-HT(1A) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

In vivo binding properties of [carbonyl-11C]WAY-100635: effect of endogenous serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

[11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Quantifying drug-related 5-HT1A receptor occupancy with

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Serotonin receptors in the human brain--III. Autoradiographic mapping of serotonin-1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Effects of endogenous neurotransmitters on the in vivo binding of dopamine and 5-HT radiotracers in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Physical performance of a positron tomograph for brain imaging with retractable septa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

G-protein coupled receptors: conformations and states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Effects of aging on 5-HT(1A) receptors and their functional response to 5-HT(1a) agonist in the living brain: PET study with [carbonyl-(11)C]WAY-100635 in conscious monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

5-HT(1A) receptor imaging in the human brain: effect of tryptophan depletion and infusion on [(18)F]MPPF binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Carbon-11 labelling of 8[[3-[4-(2-[(11)C]methoxyphenyl)piperazin-1-yl]-2-hydroxypropyl]oxy]thiochroman, a presynaptic 5-HT(1A) receptor agonist, and its in vivo evaluation in anaesthetised rat and in awake cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Effect of endogenous serotonin on the binding of the 5-hT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

Serotonin type-1A receptor imaging in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Quantitative analysis of [carbonyl-11C]WAY-100635 PET studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Pindolol occupancy of 5-HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Quantification of [Carbonyl-11C]WAY-100635 binding: considerations on the cerebellum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Radioligands for the study of brain 5-HT1A receptors in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

P-[18F]-MPPF: a potential radioligand for PET studies of 5-HT1A receptors in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Physical characteristics of the ECAT EXACT3D positron tomograph

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300390

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300390

1 reference

6 December 2017

1 reference